University Of Miami Health System

Kane Biotech has received IRB approval from the University of Miami Health System to commence a clinical study of its DispersinB® Acne Cleanser for mild to moderate Acne Vulgaris.

AION Healthspan has initiated a Phase I/II clinical trial for REJUVXL, a novel cell therapy targeting inflammation, fibrosis, and immune dysregulation in Stage 3 Chronic Kidney Disease patients.

A phase 1b trial combining luspatercept and lenalidomide demonstrates safety and preliminary efficacy in patients with non-del(5q) myelodysplastic syndrome (MDS).